Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia
Authors: Jean T. Barbey, Steven Soignet
Journal: Annals of Internal Medicine (2001)

Letters6 November 2001Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic LeukemiaJean T. Barbey, MD and Steven Soignet, MDJean T. Barbey, MDGeorgetown University; Washington, DC 20007 (Barbey)Memorial Sloan-Kettering Cancer Center; New York, NY 10021 (Soignet) and Steven Soignet, MDGeorgetown University; Washington, DC 20007 (Barbey)Memorial Sloan-Kettering Cancer Center; New York, NY 10021 (Soignet)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-9-200111060-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:While we fully concur with Ohnishi and colleagues (1) that patients receiving arsenic trioxide need close monitoring, we cannot endorse the strategy they suggest to minimize the cardiac risks associated with arsenic therapy.The authors state that asymptomatic monomorphic ventricular tachycardia developed in 4 of 8 patients during arsenic therapy and was associated with a moderately prolonged QT interval. In fact, 2 of these patients had known preexisting ventricular arrhythmias. For the 2 other patients, it seems difficult in the absence of prolonged baseline recordings to determine whether nonsustained asymptomatic ventricular arrhythmias truly developed de novo or ...References1. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al . Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med. 2000;133:881-5. [PMID: 11103058] LinkGoogle Scholar2. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-8. [PMID: 1900101] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Jean T. Barbey, MD; Steven Soignet, MDAffiliations: Georgetown University; Washington, DC 20007 (Barbey)Memorial Sloan-Kettering Cancer Center; New York, NY 10021 (Soignet)Disclaimer: Both authors are paid consultants to Cell Therapeutics, Inc., the manufacturer of arsenic trioxide, and have participated in trials evaluating arsenic. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoProlongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia Kazunori Ohnishi , Hitoshi Yoshida , Kazuyuki Shigeno , Satoki Nakamura , Shinya Fujisawa , Kensuke Naito , Kaori Shinjo , Yota Fujita , Hirotaka Matsui , Akihiro Takeshita , Shiho Sugiyama , Hiroshi Satoh , Hajime Terada , and Ryuzo Ohno Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia Kazunori Ohnishi , Hiroshi Satoh , and Ryuzo Ohno Metrics Cited byArsenic and cardiovascular systemThe whole transcriptome analysis and the circRNA-lncRNA network construction in arsenic trioxide-treated mice myocardiumIs Arsenic Exposure a Risk Factor for Metabolic Syndrome? A Review of the Potential MechanismsBased on Activation of p62-Keap1-Nrf2 Pathway, Hesperidin Protects Arsenic-Trioxide-Induced Cardiotoxicity in MiceMitigation of arsenic induced developmental cardiotoxicity by ferulic acid in zebrafishCrocin ameliorates arsenic trioxide‑induced cardiotoxicity via Keap1-Nrf2/HO-1 pathway: Reducing oxidative stress, inflammation, and apoptosisDrug-Induced Long QT Syndrome and Torsades de PointesRealgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicityAn Overview on Arsenic Trioxide-Induced CardiotoxicityChronic arsenic intoxication diagnostic score (CAsIDS)Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic MalignanciesOmega-3 Fatty Acid Protects Against Arsenic Trioxide-Induced Cardiotoxicity In Vitro and In VivoLow-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosisArsenic-Induced Cardiovascular DiseasePhloretin ameliorates arsenic trioxide induced mitochondrial dysfunction in H9c2 cardiomyoblasts mediated via alterations in membrane permeability and ETC complexesArsenic and the Cardiovascular SystemMitigation of hepatotoxic effects of arsenic trioxide through omega-3 fatty acid in ratsCardiac complications and manifestations of chemotherapy for cancerRho-Kinase Inhibitor Y-27632 Attenuates Arsenic Trioxide Toxicity in H9c2 Cardiomyoblastoma CellsCardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevençãoCardiotoxicity associated with cancer therapy: Pathophysiology and preventionα-Lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigsRealgar bioleaching solution is a less toxic arsenic agent in suppressing the Ras/MAPK pathway in Caenorhabditis elegansCardioprotective effect of salvianolic acid B against arsenic trioxide-induced injury in cardiac H9c2 cells via the PI3K/Akt signal pathwayCardiac Conduction Block at Multiple Levels Caused by Arsenic Trioxide TherapyCardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesProtective Effect of α-Lipoic Acid Against Arsenic Trioxide–Induced Acute Cardiac Toxicity in RatsCardiac Toxicity From Systemic Cancer Therapy: A Comprehensive ReviewIntroducing a new entity: chemotherapy-induced arrhythmiaResveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivoArsenic Trioxide-Induced Apoptosis in H9c2 Cardiomyocytes: Implications in CardiotoxicityDrug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug developmentArsenic trioxide: safety issues and their managementPharmacogenetics of drug-induced arrhythmiasComparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic DrugsOverview of drug therapy for multiple myelomaThe potential of arsenic trioxide in the treatment of malignant disease: past, present, and futureArsenic trioxide for the treatment of myelodysplastic syndromesArsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedsideProlongation of cardiac repolarization by arsenic trioxide 6 November 2001Volume 135, Issue 9Page: 842KeywordsArrhythmiaArsenicDeath ratesDrugsHeart failureLongitudinal studiesMedical risk factorsMyocardial infarctionSyncopeVentricular tachycardia ePublished: 6 November 2001 Issue Published: 6 November 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...